Inhomogeneous dose escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose

References

• Aerts HJWL, van Baardwijk AAW, Petit SF , Offermann C, van Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386–92.
   PubMed Web of Science ®Google Scholar
• Abramyuk A, Tokalov S, Zöphel K, Koch A, Lazanyi KS, Gillham C, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol 2009;91:399–404.
   PubMed Web of Science ®Google Scholar
• Lievens Y, Nulens A, Gaber MA, Defraene G, De Wever W, Stroobants S, et al. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: A dose-escalation planning study. Int J Radiat Oncol Biol Phys 2011;80:306–13.
   PubMed Web of Science ®Google Scholar
• St-Hilaire J, Sévigny C, Beaulieu F, Germain F, Lavoie C, Dagnault A, et al. Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients. Radiother Oncol 2009;91:342–8.
   PubMed Web of Science ®Google Scholar
• Weiss E, Ramakrishnan V, Keall PJ. Is there a selection bias in radiotherapy dose-escalation protocols?. Int J Radiat Oncol Biol Phys 2007;68:1359–65.
   PubMed Web of Science ®Google Scholar
• Belderbos JSA, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:126–34.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324–33.
   PubMed Web of Science ®Google Scholar
• ICRU Report 50. Prescribing, recording and reporting photon beam therapy. Technical report, Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
   Google Scholar
• Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JSA, Boersma LJ, Schilstra C, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003;55:724–35.
   PubMed Web of Science ®Google Scholar
• Engelsman M, Remeijer P, van Herk M, Lebesque JV, Mijnheer BJ, Damen EM. Field size reduction enables iso-NTCP escalation of tumor control probability for irradiation of lung tumors. Int J Radiat Oncol Biol Phys 2001;51:1290–8.
   PubMed Web of Science ®Google Scholar
• Baker M, Nielsen M, Hansen O, Jahn JW, Korreman S, Brink C. Isotoxic dose escalation in the treatment of lung cancer by means of heterogeneous dose distributions in the presence of respiratory motion. Int J Radiat Oncol Biol Phys 2011;81:849–55.
   PubMed Web of Science ®Google Scholar
• Schwarz M, Alber M, Lebesque JV, Mijnheer BJ, Damen EMF. Dose heterogeneity in the target volume and intensity- modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005;62:561–70.
   PubMed Web of Science ®Google Scholar
• Gottlieb KL, Hansen CR, Hansen O, Westberg J, Brink C. Investigation of respiration induced intra- and inter- fractional tumour motion using a standard Cone Beam CT. Acta Oncol 2010;49:1192–8.
   PubMed Web of Science ®Google Scholar
• Nielsen TB, Hansen VN, Westberg J, Hansen O, Brink C. A dual centre study of setup accuracy for thoracic patients based on Cone-Beam CT data. Radiother Oncol 2012;102:281–6.
   PubMed Web of Science ®Google Scholar
• Schytte T, Hansen O, Stolberg-Rohr T, Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol 2010;49:1058–60.
   PubMed Web of Science ®Google Scholar
• Martel MK, Ten Haken RK, Hazuka MB, Kessler ML, Strawderman M, Turrisi AT, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999;24:31–7.
   PubMed Web of Science ®Google Scholar
• Webb S, Nahum AE. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol 1993;38:653–66.
   PubMed Web of Science ®Google Scholar
• Webb S. Optimum parameters in a model for tumour control probability including interpatient heterogeneity. Phys Med Biol 1994;39:1895–914.
   PubMed Web of Science ®Google Scholar
• Meijer G, Steenhuijsen J, Bal M, De Jaeger K, Schuring D, Theuws J. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp brush. Radiother Oncol 2011;100:396–401.
   PubMed Web of Science ®Google Scholar
• van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012;104:67–71.
   PubMed Web of Science ®Google Scholar